Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Synovial | 1 | 2024 | 22 | 0.220 |
Why?
|
| Margins of Excision | 1 | 2024 | 56 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.200 |
Why?
|
| Neonatal Screening | 1 | 2024 | 190 | 0.190 |
Why?
|
| Breast Neoplasms | 5 | 2012 | 2586 | 0.180 |
Why?
|
| Hepatoblastoma | 1 | 2023 | 186 | 0.170 |
Why?
|
| Congenital Abnormalities | 1 | 2024 | 307 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 1 | 2023 | 210 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2022 | 382 | 0.140 |
Why?
|
| Behavior Rating Scale | 1 | 2016 | 6 | 0.120 |
Why?
|
| Executive Function | 1 | 2016 | 121 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 875 | 0.110 |
Why?
|
| Nutritional Status | 1 | 2016 | 299 | 0.110 |
Why?
|
| Child Behavior | 1 | 2016 | 235 | 0.110 |
Why?
|
| Child Development | 1 | 2016 | 266 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1350 | 0.100 |
Why?
|
| LIM Domain Proteins | 1 | 2012 | 65 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2012 | 287 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2012 | 86 | 0.090 |
Why?
|
| Prognosis | 5 | 2024 | 4803 | 0.090 |
Why?
|
| Cadherins | 1 | 2012 | 174 | 0.090 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2010 | 38 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 1732 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 477 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 25 | 0.070 |
Why?
|
| Mastectomy | 1 | 2008 | 74 | 0.070 |
Why?
|
| Mediator Complex | 2 | 2023 | 55 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 1326 | 0.060 |
Why?
|
| India | 2 | 2016 | 229 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2012 | 1032 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2008 | 464 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2008 | 400 | 0.060 |
Why?
|
| Recurrence | 2 | 2023 | 1422 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 325 | 0.050 |
Why?
|
| Urban Population | 2 | 2016 | 276 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1892 | 0.050 |
Why?
|
| Female | 11 | 2024 | 68765 | 0.050 |
Why?
|
| Humans | 13 | 2024 | 127501 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 805 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 196 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2024 | 14467 | 0.040 |
Why?
|
| Reoperation | 1 | 2024 | 821 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 349 | 0.040 |
Why?
|
| Stroke | 1 | 2008 | 1030 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 266 | 0.040 |
Why?
|
| Male | 6 | 2024 | 62895 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1054 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1370 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12583 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 714 | 0.040 |
Why?
|
| Middle Aged | 6 | 2022 | 27886 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 666 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 2754 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17080 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1239 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 3710 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1540 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1291 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2016 | 36 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2600 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3564 | 0.030 |
Why?
|
| Child | 3 | 2024 | 25302 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 687 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 686 | 0.030 |
Why?
|
| Ploidies | 1 | 2012 | 35 | 0.020 |
Why?
|
| Aged | 4 | 2012 | 20512 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 384 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8372 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 332 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 717 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2010 | 25 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 26 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 269 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 92 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2623 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2010 | 241 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 283 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1388 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 6716 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 425 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1206 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 611 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2008 | 111 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12811 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2010 | 742 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1218 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 20156 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1055 | 0.010 |
Why?
|
| Adult | 3 | 2012 | 30603 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 882 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2814 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5161 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2008 | 1198 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2110 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 886 | 0.010 |
Why?
|
| United States | 1 | 2016 | 11425 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 4309 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2008 | 4987 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 9702 | 0.010 |
Why?
|